Skip to main content

Invitae Corp

NVTADelisted Feb 21, 2024
Industry
Services-Medical Laboratories
SEC CIK
0001501134

Invitae Corp was delisted on Feb 21, 2024; its insiders filed their last Form 4 on Dec 21, 2023; 203 institutions reported holding it in 13F filings for Q4 2023, worth $97.7M in total; ARK Invest was the only superinvestor holding it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
203
Q4 2023, −13 vs. previous quarter
13F value
$97.7M
Reported value at the end of Q4 2023
Superinvestors holding
1
At the end of Q4 2023

From SEC filings, in USD.

Revenue, FY2022
$516.3M
+12.1% year over year
Net income, FY2022
-$3.11B
No comparable prior period
Free cash flow, FY2022
-$546.3M
No comparable prior period
Revenue, Q3 FY2023
$121.2M
−9.2% year over year

Revenue flow, FY2022

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2022: $3.11B (601.6% of revenue).

Superinvestors holding NVTA, Q4 2023

Go to the superinvestors tab

1 superinvestor reports holding Invitae Corp on Form 13F. Percentages are the stock's share of each portfolio.

ARK Invest

Cathie Wood

0.1%

Invitae Corp's share of the portfolio

Shares
32,550,683
Value
$20.4M

Latest insider trades

See all insider trades

Open-market purchases and sales by Invitae Corp insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 15, 2023 (view filing)Jun 132 daysNussbaum Robert LChief Medical OfficerSSale−7.09K$1.38−$9.78K−1.2%569.3K after
Jun 15, 2023 (view filing)Jun 132 daysBrida ThomasSee RemarksSSale−7.08K$1.38−$9.77K−1.0%704.1K after
May 24, 2023 (view filing)May 168 daysWen YafeiChief Financial OfficerSSale−43.5K$1.20−$52.1K−5.8%700.3K afterAmended
May 18, 2023 (view filing)May 162 daysKnight Kenneth D.Chief Executive OfficerSSale−45.4K$1.20−$54.5K−2.6%1.67M after
May 18, 2023 (view filing)May 162 daysNussbaum Robert LChief Medical OfficerSSale−26.5K$1.20−$31.8K−4.4%576.4K after
May 18, 2023 (view filing)May 162 daysWerner Robert F.Chief Accounting OfficerSSale−21.6K$1.20−$25.9K−5.7%354.7K after
May 18, 2023 (view filing)May 162 daysBrida ThomasSee RemarksSSale−26.5K$1.20−$31.8K−3.6%711.2K after
Mar 15, 2023 (view filing)Mar 132 daysBrida ThomasSee RemarksSSale−2.63K$1.41−$3.70K−0.6%437.6K after
Mar 15, 2023 (view filing)Mar 132 daysNussbaum Robert LChief Medical OfficerSSale−2.63K$1.41−$3.70K−0.6%447.9K after
Mar 15, 2023 (view filing)Mar 132 daysWen YafeiChief Financial OfficerSSale−2.63K$1.41−$3.70K−0.6%443.7K after

Top 10 13F holders, Q4 2023

See all 203 holders

The largest institutional positions in Invitae Corp at the end of Q4 2023; share changes are against Q3 2023.

Institutions holding NVTA in Q4 2023
InstitutionSharesValue% of portfolioChange in sharesAction
ARK Investment Management LLCSuperinvestorARK Invest32,550,683$20.4M0.12%−391,923−1.2%Reduced
BlackRock Inc.19,258,772$12.1M0.00%−1,539,207−7.4%Reduced
Nikko Asset Management Americas, Inc.16,764,480$10.6M0.10%00.0%Unchanged
Sumitomo Mitsui Trust Holdings, Inc.16,764,480$10.5M0.01%00.0%Unchanged
Vanguard Group Inc14,660,153$9.19M0.00%+1,132,646+8.4%Added
State Street Corp6,177,962$3.87M0.00%−1,780,985−22.4%Reduced
Geode Capital Management, LLC5,574,850$3.49M0.00%+450,651+8.8%Added
D. E. Shaw & Co., Inc.3,070,708$1.92M0.00%+2,629,153+595.4%Added
Northern Trust Corp2,311,047$1.45M0.00%+69,558+3.1%Added
Renaissance Technologies LLC2,197,698$1.38M0.00%+2,197,698New